Puma Biotech (PBYI) Defended at Citi
- Wall Street rises, buoyed by economic data; Dow sets high
- Twitter (TWTR) 'Takeover Money' Moves On as 'Trump Money' Moves In
- Amazon (AMZN) Could Open Over 2,000 Brick-and Mortar Groceries if Tests Succeed - DJ; Kroger (KR) on Watch
- Buy Any Seasonal Market Weakness Ahead of Year End Rally - Oppenheimer (SPY)
- After-Hours Stock Movers 12/05: (TXMD) (COUP) (BOBE) Higher; (SB) (LXRX) (STWD) Lower (more...)
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Puma Biotech (NYSE: PBYI) defended at Citi following massive sell-off on abstract data.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LPL Financial (LPLA) Weakens as CEO Retirement Said to Hint That Sale is Off
- Jefferies Raises Price Target on Teleflex (TFX) Ahead of Vascular Solutions (VASC) Acquisition
- KLR Group Raises Price Target on PDC Energy (PDCE) to $90
Create E-mail Alert Related CategoriesAnalyst Comments, Hot Comments, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!